tbuckley/cabot-search huggingface dataset:
Gemcitabine metabolite, 2’,2’-difluorodeoxyuridine (dFdU), can be phosphorylated and incorporated into nucleic acids
Authors: Stephan Veltkamp, Maria van Eijndhoven, Dick Pluim, Maria Bolijn, Robert Jansen, Ignacio Garcia-Ribas, Enaksha Wickremsinhe, Jos Beijnen, Jan Schellens
Journal: Cancer Research (2007)

1541  Background: Gemcitabine (2’,2’-difluorodeoxycytidine, dFdC), a pyrimidine antimetabolite, is actively transported into the cell and phosphorylated by deoxycytidine kinase (dCK) to its monophosphate (dFdCMP) and subsequently to its active diphosphate (dFdCDP) and triphosphate (dFdCTP) metabolites. dFdC is metabolised by cytidine deaminase (CDA) to 2’,2’-difluorodeoxyuridine (dFdU), which is currently considered an inactive metabolite. In a Phase 1 clinical trial of daily oral dFdC, it was observed that dFdU is extensively formed and accumulates with large exposures having a long terminal half-life. We hypothesized that dFdU might be phosphorylated to dFdUTP and incorporated into nucleic acids mediating toxicity or antitumor activity.  Methods: We assessed the in vitro toxicity, uptake, and intracellular activation of dFdC and dFdU in human hepatoma (HepG2), human lung (A549) carcinoma, and Madin-Darby canine kidney (MDCK) cell lines. The latter is a modified line with high expression of either the human equilibrative or concentrative type 1 nucleoside transporter (hENT1 and hCNT1) compared to the mock-transfected cells. Cytototoxicity was assessed at different exposure times using SRB and colony formation assays. The total cellular uptake plus incorporation into DNA/RNA of radiolabeled dFdC (0-20µM) and dFdU (0-1000µM) was determined at different time points. Intracellular and extracellular concentrations of dFdC, dFdU and phosphorylated metabolites were quantified by HPLC-UV-scintillation counting. In addition, quantitative RT-PCR was used to determine gene expression of dCK, CDA, hENT1 and hCNT1.  Results: Compared to A549 cells, HepG2 cells had a 4-fold and 7-fold higher sensitivity to dFdC and dFdU, respectively. HepG2 cells also presented higher expression levels of both hENT1 and dCK compared to A549 cells. Moreover, hENT1 andhCNT1 overexpression increased sensitivity to dFdC and in particular hCNT1 increased toxicity of dFdU. We found that dFdU is substrate for uptake by hCNT1 but not hENT1. About 4% of the accumulated amount of dFdU was detected in DNA and RNA after 16 h. dFdUTP was formed intracellularly, suggesting phosphorylation of dFdU and/or dFdUMP.  Conclusions: dFdU is toxic to HepG2 cells and to a lesser extent to A549 cells. Furthermore, dFdU is transported into cells via hCNT1, dFdUTP is formed intracellularly and is incorporated into nucleic acids. This could be relevant for the in vivo activity and toxicity of dFdC and dFdU, especially in tissues with high expression of hCNT1, such as liver and kidney. Currently, in vivo mice studies are performed to assess biodistribution of dFdC, dFdU, and phosphorylated metabolites.
MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma
Authors: M. Vos, R. Boers, A.L.M. Vriends, J. Boers, P.F. van Kuijk, W. Van Houdt, G J L H van Leenders, M. Wagrodzki, W.F.J. van IJcken, J. Gribnau, D.J. Grünhagen, C. Verhoef, S. Sleijfer, E.A.C. Wiemer
Journal: Annals of Oncology (2019)
Abstract 3798: Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells
Authors: Mireia Uribe-Herranz, Kyle Bittinger, Stavros Rafail, Sonia Guedan, Stefano Pierini, Ceylan Tanes, Saar A. Gill, Janos Tany, Mark A. Morgan, Frederic D. Bushman, Carl H. June, Andrea Facciabene
Journal: Cancer Research (2018)

Abstract Adoptive T-Cell therapy (ACT) is a promising new modality for malignancies. Here, we report that adoptive T-cell efficacy in tumor-bearing mice is significantly affected by differences in the native composition of the gut microbiome, treatment with antibiotics or by heterologous fecal transfer. Depletion of bacteria with vancomycin, decreased the rate of tumor growth in mice receiving ACT, whereas treatment with neomycin and metronidazole had no effect, indicating the role of specific bacteria in host response. Vancomycin treatment induced an increase in systemic CD8α+ dendritic cells, which mediated a sustained systemic expansion of adoptively transferred antitumor T cells in an IL-12-dependent manner. In subjects undergoing allogeneic hematopoietic cell transplantation, we found that oral vancomycin also increased IL-12 levels. Collectively, our findings demonstrate an important role played by the gut microbiota in the antitumor effectiveness of ACT and suggest new avenues to improve response to ACT by altering the gut microbiota. Citation Format: Mireia Uribe-Herranz, Kyle Bittinger, Stavros Rafail, Sonia Guedan, Stefano Pierini, Ceylan Tanes, Saar A. Gill, Janos Tany, Mark A. Morgan, Frederic D. Bushman, Carl H. June, Andrea Facciabene. Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3798.
Evaluation of a radiomic signature of CD8 cells in patients treated with immunotherapy-radiotherapy in three clinical trials
Authors: R. Sun, A. Lancia, N.L. Sundahl, M. Milic, A. Carre, M. Lerousseau, T. Estienne, E. Battistella, G. Klausner, R. Bahleda, E. Alvarez-Andres, C. Robert, C. Boutros, M. Vakalopoulou, N. Paragios, P. Ost, C. Massard, E. Deutsch
Journal: Annals of Oncology (2019)
Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)
Authors: J.F. Vansteenkiste, J. Naidoo, C. Faivre-Finn, M. Özgüroğlu, A. Villegas, D. Daniel, S. Murakami, R. Hui, K.H. Lee, B.C. Cho, K. Kubota, M. Taboada, C. Wadsworth, P.A. Dennis, S.J. Antonia
Journal: Annals of Oncology (2019)
Immune checkpoint inhibitors (ICIs) as “chemotherapy (Ctx) sensitization” strategy in advanced solid tumours
Authors: F J Ros Montana, I. Matos, G. Vilacampa, A. Azaro, J. Martin-Liberal, C. Hierro, I. Brana, C. Viaplana, M Vieito Villar, I. Gardeazabal, C. Saura, L Fariñas Madrid, T Macarulla Mercade, O. Saavedra, N. Pardo, M Ochoa de Olza, E. Muñoz-Couselo, J. Tabernero, R. Dienstmann, E. Garralda
Journal: Annals of Oncology (2019)
Safety and clinical activity of subcutaneously (SC) administered anti-PD-1 antibody PF-06801591 in phase I dose-expansion cohorts of locally advanced or metastatic non-small cell lung cancer (NSCLC) and urothelial carcinoma (UC)
Authors: B.C. Cho, K. Penkov, I. Bondarenko, M. Korozan, A. Kurochkin, J. Pikiel, Y. Kulyaba, H.K. Ahn, S. Odintsova, J. Davda, A. Forgie, X. Wang, R. Li, I.A. Jacobs, F. Kazazi, J. Chou, M.L. Johnson
Journal: Annals of Oncology (2019)
Overall survival (OS) and metastasis-free survival (MFS) in men with biochemically relapsed (BCR) prostate cancer after radical prostatectomy (RP) managed with deferred androgen deprivation treatment (ADT): A combined Johns Hopkins and CPDR study
Authors: C.H. Marshall, Y. Chen, J. Cullen, I. Rosner, M. Markowski, B. Trock, M. Eisenberger
Journal: Annals of Oncology (2019)
Avoiding Harm From Hyperbilirubinemia Screening
Authors: Thomas B. Newman, Alex R. Kemper
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Sequencing the Events That Mediate Progression of Premalignant Lung Lesions
Authors: Daniel T. Merrick
Journal: Cancer Research (2019)

Abstract Analysis of a large group of patients with multifocal premalignant disease by Krysan and colleagues in this issue of Cancer Research provides an informative view of the processes that may underlie progression of these lesions to invasive adenocarcinoma of the lung. The identification of the type and distribution of mutational changes reveals that common processes may be occurring within individuals but that these are generally unique between patients at risk for developing lung cancer. Furthermore, predicted neoantigens are identified and associated with characteristics of immune infiltrates supporting the role of alterations in adaptive immune surveillance in progression of these premalignant lesions. These findings provide critical insights that will help establish a foundation of knowledge for developing personalized prevention strategies with the potential to significantly impact overall mortality in lung cancer. See related article by Krysan et al., p. 5022
cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
Authors: S.K. Pal, D.F. Bajorin, J.H. Hoffman-Censits, D.I. Quinn, D.P. Petrylak, M.D. Galsky, U.N. Vaishampayan, U. De Giorgi, S. Gupta, H.A. Burris, H.S. Soifer, G. Li, C.L. Dambkowski, S. Moran, H. Wang, S. Daneshmand, J.E. Rosenberg
Journal: Annals of Oncology (2019)
High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: First results of the AcSé pembrolizumab study
Authors: J.-Y. Blay, N. Penel, I.L. Ray-Coquard, R. Schott, E. Saada-Bouzid, F. Bertucci, C.M. Chevreau, E. Bompas, E. Coquan, S. Cousin, P. Soulié, A. Le Cesne, O. Mir, T. Ryckewaert, M. Brahmi, N. Hoog-Labouret, D. Couch, S. Chevret, J.-C. Soria, C. Massard
Journal: Annals of Oncology (2019)
Independent clinical validation of a gene expression profile to predict benefit of 5-FU in metastatic colorectal cancer
Authors: I.K. Buhl, G.U. Carlsson, P. Saksena, B. Gustavsson, I.J. Christensen, A. Edsjö, A. Hansen, S. Knudsen, P.B. Jensen, Y. Wettergren
Journal: Annals of Oncology (2019)
Neutrophil to lymphocyte ratio (NLR) kinetics as predictors of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (NSCLC) patients treated with nivolumab (N)
Authors: A. Simonaggio, R. Elaidi, L. Fournier, E. Fabre, V. Ferrari, D. Borchiellini, C. Thibault, P. Barthelemy, J. Thouvenin, E. Tartour, S. Oudard, Y. Vano
Journal: Annals of Oncology (2019)
CRYODESMO-O1: A French nationwide phase II study on cryoablation in progressing desmoid tumour (DT) patients (pts)
Authors: J.-E. Kurtz, X. Buy, E.A. Sauleau, M. Toulmonde, F. Deschamps, C. Honoré, A. Bouhamama, J.-Y. Blay, A. Gangi
Journal: Annals of Oncology (2019)
Phase I study of liposomal formulation of eribulin (E7389-LF) in patients (pts) with advanced solid tumours: Primary results of dose-escalation part
Authors: N. Yamamoto, J. Sato, T. Koyama, S. Iwasa, A. Shimomura, S. Kondo, S. Kitano, K. Yonemori, Y. Fujiwara, K. Tamura, T. Suzuki, T. Takase, Y. Nishiwaki, K. Nakai, T. Shimizu
Journal: Annals of Oncology (2019)
Deep Learning Approaches Predict Glaucomatous Visual Field Damage from OCT Optic Nerve Head En Face Images and Retinal Nerve Fiber Layer Thickness Maps
Authors: Mark Christopher, Christopher Bowd, Akram Belghith, Michael H. Goldbaum, Robert N. Weinreb, Massimo A. Fazio, Christopher A. Girkin, Jeffrey M. Liebmann, Linda M. Zangwill
Journal: Ophthalmology (2019)
Phase I combination dose-finding/phase II expansion cohorts of lenvatinib + etoposide + ifosfamide in patients (pts) aged 2 to ≤ 25 years with relapsed/refractory (r/r) osteosarcoma
Authors: N. Gaspar, F J Bautista Sirvent, R. Venkatramani, A. Longhi, C. Lervat, M. Casanova, I. Aerts, S.S. Bielack, N. Entz-Werle, S. Strauss, C. He, E. Thebaud, F. Locatelli, B. Morland, S Gallego Melcon, A Cañete Nieto, P. Marec- Bérard, M. Gambart, C. Rossig, Q. Campbell-Hewson
Journal: Annals of Oncology (2019)
Frequency of mutations in 21 hereditary breast and ovarian cancer susceptibility genes among 882 high-risk individuals
Authors: J. Liu, D. Shao, S. Cheng, F. Guo, Y. Yuan, K. Hu, Z. Wang, X. Meng, X. Jin, X. Yun, X. Chai, H. Li, Y. Zhang, H. Zhang, M. Ye
Journal: Annals of Oncology (2019)
Updated results of NORDIC 8, a randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer
Authors: P. Pfeiffer, J.K. Bjerregaard, C. Qvortrup, H. Sorbye, B. Glimelius, C. Kersten
Journal: Annals of Oncology (2019)
Response to: ‘Do the 2019 EULAR/ACR SLE classification criteria close the door on certain groups of SLE patients?’ by Chi<i>et al</i>
Authors: Martin Aringer, Karen H Costenbader, Thomas Dörner, Sindhu R Johnson
Journal: Annals of the Rheumatic Diseases (2019)

In their letter, Dr Chi and colleagues1 express two concerns regarding the new European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria. On the one hand, they correctly remark that patients with uncommon, isolated organ manifestations may be more difficult to classify with any set of classification criteria. On the other hand, they caution against mistaking malignancies for systemic lupus erythematosus (SLE).

The first sensitivity-related issue is certainly correct. However, it is important to reiterate that the new EULAR/ACR criteria are classification …
Middle East &amp; North Africa registry to characterize RAS mutation status and tumour specifications in recently diagnosed patients with metastatic colorectal cancer (MORE-RAS Study)
Authors: M. Oukkal, K. Bouzid, A. Bounedjar, A. Alnajar, F Abou Taleb, A. Alsharm, H. Mahfouf, B. Larbaoui, A. Abdelaziz, A. Ouamer, L. Bashir
Journal: Annals of Oncology (2019)
Serum Beta Carotene and Overall and Cause-Specific Mortality
Authors: Jiaqi Huang, Stephanie J. Weinstein, Kai Yu, Satu Männistö, Demetrius Albanes
Journal: Circulation Research (2018)

Rationale: Although the health effects of beta carotene have been studied extensively, a systematic examination of serum concentrations and long-term mortality, including cardiovascular disease mortality, has not been reported. Objective: Explore whether serum beta carotene is associated with overall and cause-specific mortality and to elucidate the strength and dose-response of the association. Methods and Results: We conducted a prospective serological analysis of 29 103 men in the ATBC study (Alpha-Tocopherol, Beta-Carotene Cancer Prevention). During 31 years of follow-up, 23 796 deaths occurred, including deaths because of cardiovascular disease (9869), cancer (7692), respiratory disease (2161), diabetes mellitus (119), injuries and accidents (1255), and other causes (2700). Serum beta carotene was assayed using high-performance liquid chromatography. Adjusting for major risk factors measured, men with higher serum beta carotene had significantly lower all-cause mortality (hazard ratios=0.81, 0.71, 0.69, and 0.64 for quintile 2 (Q2)-Q5 versus Q1, respectively; P trend &lt;0.0001). Serum beta carotene was significantly associated with risk of death from cardiovascular disease, heart disease, stroke, cancer, respiratory disease, diabetes mellitus, injuries and accidents, and other causes (Q5 versus Q1, hazard ratio=0.21–0.73, all P trend &lt;0.0001). The all-cause mortality association was not materially impacted by adjustment for fruit and vegetable consumption (albeit, estimated with some measurement error) and was generally similar across subgroups of smoking intensity, alcohol consumption, trial supplementation, and duration of follow-up, but was significantly modified by age, years of smoking, and body mass index, with stronger inverse associations among men who were younger, smoked fewer years, and had a lower body mass index (all P interaction ≤0.0025). Conclusions: This study provides evidence that higher beta carotene biochemical status is associated with lower overall, cardiovascular disease, heart disease, stroke, cancer, and other causes of mortality. The dose-response associations over a 30-year period were not attenuated by adjustment for other important risk factors and support greater fruit and vegetable consumption as a means to increase beta carotene status and promote longevity.
A prospective correlative trial of personalized patient-derived xenograft (PDX) as avatars for drug therapy in patients with metastatic or recurrent soft tissue sarcomas (STS)
Authors: K. Alshammari, E.M. Al-ezzi, J. Lewin, S. Salah, Z.W.N. Veitch, E. Malone, G. Paris, M. Mancini, A. Zer, M. Ahmad, R. Beercroft, A.R.R. Albiruni
Journal: Annals of Oncology (2019)
Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1)
Authors: Tatjana Meyer, Nikolaus Jahn, Stefanie Lindner, Linda Röhner, Anna Dolnik, Daniela Weber, Annika Scheffold, Simon Köpff, Peter Paschka, Verena I. Gaidzik, Dirk Heckl, Sebastian Wiese, Benjamin L. Ebert, Hartmut Döhner, Lars Bullinger, Konstanze Döhner, Jan Krönke
Journal: Leukemia (2019)

Abstract BRCA1/BRCA2-containing complex 3 ( BRCC3 ) is a Lysine 63-specific deubiquitinating enzyme (DUB) involved in inflammasome activity, interferon signaling, and DNA damage repair. Recurrent mutations in BRCC3 have been reported in myelodysplastic syndromes (MDS) but not in de novo AML. In one of our recent studies, we found BRCC3 mutations selectively in 9/191 (4.7%) cases with t(8;21)(q22;q22.1) AML but not in 160 cases of inv(16)(p13.1q22) AML. Clinically, AML patients with BRCC3 mutations had an excellent outcome with an event-free survival of 100%. Inactivation of BRCC3 by CRISPR/Cas9 resulted in improved proliferation in t(8;21)(q22;q22.1) positive AML cell lines and together with expression of AML1-ETO induced unlimited self-renewal in mouse hematopoietic progenitor cells in vitro. Mutations in BRCC3 abrogated its deubiquitinating activity on IFNAR1 resulting in an impaired interferon response and led to diminished inflammasome activity. In addition, BRCC3 inactivation increased release of several cytokines including G-CSF which enhanced proliferation of AML cell lines with t(8;21)(q22;q22.1). Cell lines and primary mouse cells with inactivation of BRCC3 had a higher sensitivity to doxorubicin due to an impaired DNA damage response providing a possible explanation for the favorable outcome of BRCC3 mutated AML patients.
Hemodynamics and Prognostic Impact of Concomitant Mitral Stenosis in Patients Undergoing Surgical or Transcatheter Aortic Valve Replacement for Aortic Stenosis
Authors: Nahoko Kato, Ratnasari Padang, Cristina Pislaru, William R. Miranda, Mizuho Hoshina, Kentaro Shibayama, Hiroyuki Watanabe, Christopher G. Scott, Kevin L. Greason, Sorin V. Pislaru, Vuyisile T. Nkomo, Patricia A. Pellikka
Journal: Circulation (2019)

Mitral stenosis frequently coexists in patients with severe aortic stenosis. Mitral stenosis severity evaluation is challenging in the setting of combined aortic stenosis and mitral stenosis because of hemodynamic interactions between the 2 valve lesions. The impact of aortic valve replacement (AVR) for severe aortic stenosis on mitral stenosis is unknown. This study aimed to assess the effect of AVR on mitral stenosis hemodynamics and the clinical outcomes of patients with severe aortic stenosis with and without mitral stenosis.We retrospectively investigated patients who underwent surgical AVR or transcatheter AVR for severe aortic stenosis from 2008 to 2015. Mean transmitral gradient by Doppler echocardiography ≥4 mm Hg was identified as mitral stenosis; patients were then stratified according to mitral valve area (MVA, by continuity equation) as >2.0 cm2 or ≤2.0 cm2. MVA before and after AVR in patients with mitral stenosis were evaluated. Clinical outcomes of patients with and without mitral stenosis were compared using 1:2 matching for age, sex, left ventricular ejection fraction, method of AVR (surgical AVR versus transcatheter AVR) and year of AVR.Of 190 patients with severe aortic stenosis and mitral stenosis (age 76±9 years, 42% men), 184 were matched with 362 with severe aortic stenosis without mitral stenosis. Among all mitral stenosis patients, the mean MVA increased after AVR by 0.26±0.59 cm2 (from 2.00±0.50 to 2.26±0.62 cm2, P<0.01). MVA increased in 105 (55%) and remained unchanged in 34 (18%). Indexed stroke volume ≤45 mL/m2 (odds ratio [OR] 2.40; 95% CI, 1.15-5.01; P=0.020) and transcatheter AVR (OR, 2.36; 95% CI, 1.17-4.77; P=0.017) were independently associated with increase in MVA. Of 107 with significant mitral stenosis (MVA ≤2.0 cm2), MVA increased to >2.0 cm2 after AVR in 52 (49%, pseudo mitral stenosis) and remained ≤2.0 cm2 in 55 (51%, true mitral stenosis). During follow-up of median 2.9 (0.7-4.9) years, true mitral stenosis was an independent predictor of all-cause mortality (adjusted hazard ratio, 1.88; 95% CI, 1.20-2.94; P<0.01).MVA improved after AVR in nearly half of patients with severe aortic stenosis and mitral stenosis. MVA remained ≤2.0 cm2 (true mitral stenosis) in nearly half of patients with severe aortic stenosis and significant mitral stenosis; this was associated with worse survival among patients undergoing AVR for severe aortic stenosis.
P2.01-42 Impact of Tobacco Smoking on Outcomes in Patients with Metastatic Non-Small Cell Lung Cancer in the Era of Targeted Therapy
Authors: M. Gutierrez, A. Wozniak, C. Langer, B. Fang, G. Suero-Abreu, A. Norden, K. Bedell, J. Schaffer, A. Collins, E. Schultz, B. Stone, V. Narayanan, S. Goldberg
Journal: Journal of Thoracic Oncology (2018)
STING agonist, ADU-S100, yields potent anti-tumour activity and therapeutically favorable immune profile in an esophageal adenocarcinoma model
Authors: A.H. Zaidi, A.N. Omstead, N. Chowdhury, J.E. Kosovec, P. Zheng, M.S. Salvitti, A. Gorbunova, L. Babar, R.J. Kelly, B.A. Jobe
Journal: Annals of Oncology (2019)
Immune classification of soft tissue sarcoma predicts clinical outcome
Authors: F. Petitprez, A. de Reyniès, E.Z. Keung, T W-W Chen, C.-M. Sun, Y.-M. Jeng, L.-P. Hsiao, L. Lacroix, C. Lucchesi, M. Toulmonde, M.A. Burgess, V. Bolejack, D. Reinke, A.J. Lazar, C.L. Roland, J. Wargo, A. Italiano, C. Sautès-Fridman, H.A. Tawbi, W.H. Fridman
Journal: Annals of Oncology (2019)
Safety and efficacy of the oral CXCR4 inhibitor X4P-001 + axitinib in advanced renal cell carcinoma patients: An analysis of subgroup responses by prior treatment
Authors: D.F. McDermott, U. Vaishampayan, M. Matrana, S.Y. Rha, A Zurita Saavedra, T. Ho, B. Keam, J.-L. Lee, R. Joseph, S. Ali, W. Stadler, N.B. Haas, S. Sundararajan, S.H. Park, R. Mowat, J. Picus, A.Z. Dudek, Y. Zakharia, L. Gan, M.B. Atkins
Journal: Annals of Oncology (2019)
Prognostic significance of elements of the adaptive immunity in the microenvironment of early-stage non-small cell lung cancer
Authors: A. Liakea, E. Tsagari, A. Spathis, A. Kampoli, J. Durán Moreno, E. Kefalidi, E. Kapetanakis, K. Kostopanagiotou, A. Koumarianou, I. Panayiotides, N. Kavantzas, P. Tomos, P. Foukas
Journal: Annals of Oncology (2019)
BISQUIT: A randomized phase II study of the administration of prebiotics and probiotics during definitive treatment with chemotherapy-radiotherapy for patients with squamous cell carcinoma of the anal canal
Authors: R.P. Riechelmann, M. Camandaroba, C.A. Mello, V.S. Silva, V.H.F. de Jesus, M. Barros, N. Rodrigues, M.D. Donadio, M. Cavichiolli, V.C.C. Lima, E. Dias-Neto, D.N. Nunes, D. Carraro, L. De Brot, S. Aguiar, M.L.G. Silva
Journal: Annals of Oncology (2019)